Japan’s Wakamoto, GSK Arm Team To Co-Market Botox
This article was originally published in PharmAsia News
Executive SummaryJapan's Wakamoto Pharmaceutical and U.K.-based GlaxoSmithKline's Japanese unit have reached a co-marketing agreement for GSK's Botox (botulinum toxin type A) beginning July 6. U.S.-based Allergan owns Botox, but GSK has the Japanese and Chinese rights to develop the drug, which has both cosmetic and medical uses, such as treating facial muscle spasms and eye blinking. With Wakamoto, GSK seeks to promote the drug for eye-related therapy. (Click here for more - a subscription may be required
You may also be interested in...
All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.